Effect of sodium-glucose co-transporter-2 inhibitor empagliflozin on disease progression in a patient with heart failure and preserved ejection fraction
Authors:
Filip Málek
Authors‘ workplace:
Kardiovaskulární centrum, Nemocnice Na Homolce, Praha
Published in:
Vnitř Lék 2023; 69(3): 189-192
Category:
Case reports
doi:
https://doi.org/10.36290/vnl.2023.032
Overview
Sodiumglucose co-transporter 2 inhibitors – gliflozins – have a scientific evidence on efficacy in patients with heart failure regardless left ventricular ejection fraction. Gliflozins They reduced combined endpoint of cardiovascular mortality and heart failure hospitalization also in patients with heart failure and left ventricular ejection fraction above 40 %. We report a case study of a patient with new onset heart failure. Early initiation of therapy with empagliflozin was associated with an improvement of symptoms and laboratory parameters including NT-proBNP level.
Keywords:
disease progression – empagliflozin – heart failure with reduced ejection fraction
Sources
1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24:4–131.
2. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/ HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895–e1032.
3. Packer M, Anker SD, Butler J, et al. For the EMPEROR‑Reduced Trial Investigators Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure N Engl J Med 2020 383,15:1413-24.
4. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021, doi: 10.1056/NEJMoa2107038.
5. Solomon SD, McMurray JJV, Claggett B, et al. For the DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 2022, 387:1089-1098.
6. Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA‑PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 2019,22:391-412
7. Duarte K, Monnez JM, Albuisson E, et al. Prognostic value of estimated plasma volume in heart failure.
8. J Am Coll Cardiol HF 2015;3:886-93.
9. Mentz RJ, Kjeldsen K, Rossi GP, et al. Decongestion in acute heart failure. Eur J Heart Fail 2014;16:471-82.
10. Pocock SJ, Ariti CA, McMurray JJV, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 2013 May;34(19):1404-13.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2023 Issue 3
Most read in this issue
- JAK inhibition in the treatment of inflammatory rheumatic diseases
- Differential diagnostics of interstitial lung diseases
- News in gastroenterology, hepatology and digestive endoscopy
- Multimorbidity in nephrotic syndrome